Edwards Lifesciences (NYSE:EW) reported Q2 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.4 billion.
GUIDANCE:
Edwards Lifesciences sees Q3 2022 EPS of $0.58-$0.66, versus the consensus of $0.65. Edwards Lifesciences sees Q3 2022 revenue of $1.3-1.37 billion, versus the consensus of $1.44 billion.